Fundraising FoxSamsara BioCapital — 2017 Investments
5 investments dated 2017 · listed companies and verified rows first · show all
aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.
BiotechHealthtechMedical DevicesSan Diego, US
Paul Schimmel(Founder)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)inFrederic Chereau(Executive Officer)
BoardAmir Nashat(Non-Management Director)inAkkaraju Srinivas(Non-Management Director)
Board seatSrini Akkaraju· per SEC Form D · $45.8M raise · filed Sep 2017
Co-investorsCardinal PartnersEcoR1 CapitalSofinnova VenturesViking GlobalDomain AssociatesDomain Partners+2 more
Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)Yung H. Chyung(Executive Officer)Elan Z. Ezickson(Executive Officer)Akshay Vaishnaw(President of Research & Development and Director)R. Keith Woods(Chief Operating Officer)in
Co-investorsARCH Venture PartnersEcoR1 CapitalPolaris Partners
Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.
BiotechSan Carlos, US
Nenad Tomasevic(Executive Officer)Christopher Bebbington(Executive Officer, Director)Alejandro Dorenbaum(Executive Officer)
BoardFarah Champsi(Director)inJohn McKearn(Director)inPeter Moldt(Director)
Co-investorsAlta PartnersLifeSci Venture PartnersNew Enterprise Associates (NEA)RiverVest Venture PartnersRoche Venture Fund
HealthtechSkokie, US
Sara Cotter(Executive Officer, Director, Promoter)Michael Dybbs(Director)Sara Brownstein(Director)Terrence Kearney(Director)Daniel Welch(Director)Steven Ryder(Director)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.